And the concluding sentence of the report is
Given the favorable benefit/risk profile for omacetaxine in adult CML patients who have the Bcr-Abl T315I mutation and have failed imatinib therapy, omacetaxine offers the only therapeutic treatment alternative for a patient population with a poor prognosis and no proven treatment options.
fda announcement in us today, page-7
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)